Coherus Reports Positive Initial Data in Ongoing Study of Humira Biosimilar to Treat Plaque Psoriasis
News
Coherus BioSciences recently reported that its ongoing Phase 3 pharmacokinetic and bioequivalence study comparing biosimilar CHS-1420, a candidate treatment for plaque psoriasis, to Humira (adalimumab) successfully met its 12-week endpoints. Specifically, the study demonstrated similarity ... Read more